Savara stock. Thin-source profile holds the focus.
Savara Inc. (SVRA) continues to focus on its rare-disease pipeline and Nasdaq listing, with its lead program being molgramostim inhalation therapy for autoimmune pulmonary alveolar proteinosis. Despite the absence of new market catalysts, the company's development pipeline and financing profile remain central to its stock story. Investors primarily monitor trial data, regulatory updates, cash runway, and development timing changes.
Enterprise value to EBIT forward of Savara, Inc. – NASDAQ:SVRA
This article provides a financial snapshot for Savara, Inc. (NASDAQ: SVRA), focusing on its enterprise value to EBIT forward. It indicates whether there have been changes in this period and by what percentage. The data is supported by various financial services and is presented via TradingView.
Enterprise value to EBITDA forward of Savara, Inc. – NASDAQ:SVRA
This article displays the Enterprise Value to EBITDA forward for Savara, Inc. (NASDAQ: SVRA) on TradingView. It indicates that the market was closed at the time of viewing, with no trades reported. The content is primarily a data point without further analytical text.
Savara Inc focuses on respiratory drug development as investors watch clinical progress
Savara Inc. is a clinical-stage biopharmaceutical company specializing in developing inhaled therapies for rare respiratory diseases. The company's strategy involves focusing on conditions with high unmet medical needs, pursuing orphan-drug designations, and advancing its pipeline through clinical trials. Investors closely monitor Savara's trial milestones, regulatory decisions, and financing activities, as the company's valuation is driven by expectations for clinical success rather than current revenue.
Price to book forward of Savara, Inc. – NASDAQ:SVRA
This article provides financial information for Savara, Inc. (NASDAQ: SVRA), specifically focusing on its forward price-to-book ratio. The content appears to be a stub or a section of a larger financial data display, indicating the period and value of this metric. It originates from TradingView, a financial charting and analysis platform.
Price to sales forward of Savara, Inc. – NASDAQ:SVRA
This page provides financial information for Savara, Inc. (NASDAQ: SVRA), specifically focusing on its price-to-sales forward metric. It appears to be a financial data snippet from TradingView, offering a quick overview of this particular financial ratio for the company.
Enterprise value to revenue forward of Savara, Inc. – NASDAQ:SVRA
The article focuses on the enterprise value to revenue forward metric for Savara, Inc. (NASDAQ: SVRA). It appears to be a stub or a placeholder, as no specific financial data or analysis is presented in the provided content, only the title and navigation elements.
Savara Inc. (SVRA) Class Action Lawsuit: Levi & Korsinsky Reminds Investors of November 7, 2025 Deadline
Levi & Korsinsky LLP has announced a class action lawsuit against Savara Inc. (NASDAQ:SVRA), reminding investors of the November 7, 2025 deadline to join. The lawsuit alleges that Savara made false and misleading statements between March 4, 2024, and May 23, 2025, regarding the regulatory approval and chemistry, manufacturing, and controls of its drug MOLBREEVI, which impacted its stock value. Investors who suffered losses on their Savara Inc. shares during this period are encouraged to seek information about their recovery rights.
Levi & Korsinsky Notifies Savara Inc. (SVRA) Investors - Lead Plaintiff Deadline on November 7, 2025
Levi & Korsinsky has announced a class action securities lawsuit against Savara Inc. (SVRA), urging investors who suffered losses between March 4, 2024, and May 23, 2025, to come forward by the lead plaintiff deadline of November 7, 2025. The lawsuit alleges that Savara made false statements and concealed issues with its MOLBREEVI BLA submission, including insufficient manufacturing information and a likely delay in regulatory approval, which would necessitate raising additional capital. Investors are encouraged to learn more about their rights to seek recovery for alleged securities fraud.
Securities Lawsuit Alert: Savara Inc. (SVRA) Investors - Contact Levi & Korsinsky Before November 7, 2025
Levi & Korsinsky LLP has announced a securities lawsuit alert for investors of Savara Inc. (NASDAQ:SVRA). The class action seeks to recover losses for shareholders affected by alleged securities fraud between March 4, 2024, and May 23, 2025, primarily concerning misstatements about the MOLBREEVI BLA and its regulatory approval timeline. Investors who suffered losses are encouraged to contact the firm before November 7, 2025, to learn about their rights to seek recovery.
Class Action Lawsuit Alert: Levi & Korsinsky Reminds Savara Inc. (SVRA) Investors of November 7, 2025 Deadline
Levi & Korsinsky LLP has issued a class action lawsuit alert for investors of Savara Inc. (NASDAQ: SVRA). The lawsuit, filed on behalf of shareholders who experienced losses between March 4, 2024, and May 23, 2025, alleges the company made false statements regarding its MOLBREEVI BLA and potential FDA approval issues. Investors have until November 7, 2025, to seek recovery.
Investors in Savara Inc. (SVRA): Protect Your Rights - Contact Levi & Korsinsky Before November 7, 2025
Levi & Korsinsky LLP has announced a class action securities lawsuit against Savara Inc. (SVRA) for alleged securities fraud between March 4, 2024, and May 23, 2025. The lawsuit claims Savara made false statements regarding its MOLBREEVI BLA treatment, suggesting insufficient chemistry, manufacturing, and controls information that would likely prevent FDA approval in its current form. Shareholders who suffered losses during this period are encouraged to contact Levi & Korsinsky before November 7, 2025, to learn about a potential recovery.
SVRA Forecast — Price Target — Prediction for 2027
This article provides a forecast and price target for Savara, Inc. (SVRA) stock, based on analyst ratings and historical performance. It details current and historical stock prices, market capitalization, volatility, and future earnings estimates. The article also includes a Q&A section addressing common investor questions about SVRA.
Savara, Inc. Actuals & Estimates (FWB:YB4P)
This article provides an overview of Savara, Inc. (FWB: YB4P) including financial actuals and estimates, stock forecasts, and frequently asked questions. It details analyst price targets, historical stock performance, upcoming earnings dates, recent earnings per share, and revenue figures.
What Does the FDA's Priority Review Mean for Savara's MOLBREEVI
Savara Inc. achieved a significant milestone with the FDA’s Priority Review for its Biologics License Application (BLA) for MOLBREEVI, setting an August 22, 2026, PDUFA date. MOLBREEVI, targeting autoimmune pulmonary alveolar proteinosis (aPAP), addresses a rare lung disease with no approved therapies, presenting a substantial first-mover market opportunity. While the potential upside is considerable, investors must weigh regulatory approval against commercialization risks and the company's pre-revenue financial profile.
YB4P Forecast — Price Target — Prediction for 2027
The article provides a forecast and price target for Savara, Inc. (YB4P) stock on the Frankfurt Stock Exchange. It includes analyst ratings, estimated future prices, historical stock performance, and key financial data such as earnings per share and revenue. The report also addresses frequently asked questions about the company's ticker, earnings dates, and dividend policy.
Form 4 Savara Inc For: 22 June By Investing.com
This article from Investing.com reports that Savara Inc. filed a Form 4 for insider transactions on June 22. The brief notice includes the stock symbol SVRA, which showed a 1.58% increase. The article provides minimal detail beyond the filing reference.
Savara CFO David Lowrance sells $2.24m in company stock By Investing.com
Savara CFO David Lowrance sold 394,528 shares of the company's common stock for approximately $2.24 million and acquired 580,187 shares through stock options for about $1.02 million. Following these transactions, including share dispositions for tax liabilities, Lowrance directly holds 536,032 shares. The company has also announced leadership changes with Lowrance stepping down due to health reasons and Robert Lutz taking on the CFO role, while also reporting positive data from its IMPALA-2 Phase 3 clinical trial.
Savara CFO David Lowrance sells $2.24m in company stock By Investing.com
Savara CFO David Lowrance sold 394,528 shares of company stock worth $2.24 million but simultaneously acquired 580,187 shares through stock options, also disposing of shares to cover tax liabilities. This comes as Lowrance is set to step down due to health reasons, with COO Robert Lutz taking over as CFO. The company also recently approved doubling its authorized shares and presented positive data from its IMPALA-2 Phase 3 clinical trial.
Form 4 Savara Inc For: 22 June By Investing.com
The article reports on a Form 4 filing for Savara Inc. (SVRA) dated June 22. It is a brief financial news item from Investing.com, typical of filings news. The article notes a 3.45% increase for Savara Inc. stock.
Savara (SVRA) CFO exercises 580K options and sells 394K shares in Form 4
Savara Inc.'s CFO, David L. Lowrance, exercised 580,187 stock options and sold 394,528 shares of common stock in an open-market transaction on June 22, 2026, at a weighted average price of $5.6813 per share. Additionally, 185,659 shares were withheld to cover tax obligations. Following these transactions, Lowrance directly owns 536,032 shares of Savara common stock, indicating a significant and active equity stake in the company.
[144] Savara Inc SEC Filing
This SEC filing for Savara Inc. (SVRA) is a Form 144, indicating a notice of proposed sale of securities under Rule 144. The filing details the sale of 394,528 common shares with an aggregate market value of $2,229,000.00, through Raymond James & Associates on June 22, 2026, obtained via a cashless stock option exercise.
Does Savara’s Expanded Share Pool and CFO Shift Reframe Its Capital Strategy Narrative (SVRA)?
Savara Inc. recently gained stockholder approval to double its authorized common shares to 600,000,000 and announced that CFO Dave Lowrance would depart due to health reasons, with COO Robert Lutz assuming the CFO role. These changes introduce capital flexibility and leadership continuity but also raise concerns about potential dilution for existing shareholders, given the company's pre-revenue status and reliance on MOLBREEVI's regulatory success. The market's focus remains on Molina's BLA review and ex-US decisions rather than immediate governance changes, with analysts suggesting Savara's current valuation might be inflated.
Savara Inc (SVRA) Valuation: PE, PB & Fair Value Analysis
This article provides a valuation analysis of Savara Inc (SVRA), noting its current valuation score of 7.70, ranking 207 out of 388 in the Biotechnology & Medical Research industry. The company's P/E ratio stands at -9.49, which is significantly below its recent high and above its recent low. The article also indicates that relevant data for P/B, P/S, and P/CF ratios have not yet been disclosed by Savara Inc.
Savara Inc (SVRA) Technical Analysis: Support, Resistance, Indicators & Moving Averages
This article provides a technical analysis of Savara Inc (SVRA), focusing on its support and resistance levels, various technical indicators, and moving averages. As of June 16, 2026, SVRA has a price momentum score of 8.99 and is trading between a resistance level of 5.65 and a support level of 4.82. The analysis indicates a "Buy" signal based on moving averages and a mix of buy, sell, and neutral signals from other technical indicators.
Savara Inc (SVRA) Financial Health: Profitability & Balance Sheet Analysis
This article analyzes the financial health of Savara Inc (SVRA), assigning it a weak financial score of 5.22 out of 388 in the Biotechnology & Medical Research industry, indicating low operating efficiency. Key financial metrics such as cash and cash equivalents, total assets, total liabilities, and free cash flow are mentioned, although the company has not yet disclosed relevant data for several categories. The analysis highlights the company's lack of disclosed operational and growth data, impacting its overall financial assessment.
Savara (SVRA) Proxy filing Summary
Savara (SVRA) has scheduled its annual meeting for June 4, 2026, where shareholders will vote on board elections, an increase in authorized common stock, amendments to incentive plans, auditor ratification, and executive compensation. The company is preparing for the potential commercial launch of molgramostim inhalation solution (MOLBREEVI) for autoimmune PAP, with regulatory reviews underway in the US, EU, and UK. Recent financial activities include equity financing, a royalty funding agreement, and an amended debt facility, aligning with its strategic focus on MOLBREEVI's market entry.
Savara Inc (SVRA) Earnings Forecast: Future EPS & Revenue Growth Estimates
Savara Inc (SVRA) has an earnings forecast score of 8.75, ranking high within its industry. Analysts have set an average price target of $10.25, with a consensus "Buy" rating based on 8 analysts. The company's previous quarter's EPS outperformed market expectations, and the next quarter's EPS is also projected.
Savara Announces New Employment Inducement Grant
Savara Inc. announced inducement awards granted to four new employees on June 11, 2026. These awards include options to purchase 36,500 shares, restricted stock units covering 42,500 shares, and performance stock units for 8,000 shares, intended to induce their employment. The grants were made under the Savara Inc. 2021 Inducement Equity Incentive Plan, following NASDAQ Listing Rules, with specific vesting schedules tied to continued employment and company performance.
How Investors Are Reacting To Savara (SVRA) Doubling Share Authorization And Reshaping Its CFO Role
Savara Inc. recently gained stockholder approval to double its authorized common shares to 600 million, while its CFO is stepping down and the COO will assume the finance role. These changes provide Savara with greater flexibility for equity raises, potentially leading to dilution, but the CFO transition to an experienced COO signals continuity in funding strategy. Investors should be aware of the increased potential for dilution, as the current stock price might be inflated according to some analysis.
How Investors Are Reacting To Savara (SVRA) Doubling Share Authorization And Reshaping Its CFO Role
Savara Inc. stockholders recently approved doubling the company's authorized common shares to 600 million, while Chief Financial and Administrative Officer Dave Lowrance announced his departure for health reasons. COO Robert Lutz will assume the CFO role, bringing capital markets experience. These changes give Savara flexibility for equity raises, potentially leading to dilution, which investors should monitor closely given the company's current lack of revenue and ongoing net losses.
Savara shareholders approve share increases and executive changes at annual meeting
Savara Inc. shareholders approved an increase in authorized common stock from 300 million to 600 million shares and an additional 18.9 million shares for its 2024 Omnibus Incentive Plan. The company also announced executive changes, with Robert Lutz appointed as Chief Financial and Operating Officer, replacing David Lowrance who is stepping down for health reasons. Additionally, Savara provided updates on its Phase 3 IMPALA-2 clinical trial for molgramostim and the FDA's extended review of its biologics license application.
Savara shareholders approve share increases and executive changes at annual meeting By Investing.com
Savara Inc. shareholders have approved an increase in authorized common stock from 300 million to 600 million shares and an additional 18.9 million shares for its incentive plan. The company also announced executive changes, with Robert Lutz appointed as Chief Financial and Operating Officer following David Lowrance's resignation due to health reasons. Other proposals, including director elections and auditor ratification, were also approved at the annual meeting.
Savara shareholders approve share increases and executive changes at annual meeting
Savara Inc. shareholders approved significant corporate changes including doubling authorized common stock to 600 million shares and increasing shares for its Omnibus Incentive Plan. The company also announced the appointment of Robert Lutz as Chief Financial and Operating Officer, replacing David Lowrance who resigned due to health reasons. These decisions follow recent developments regarding Savara's Phase 3 IMPALA-2 clinical trial for molgramostim and an FDA extension for its biologics license application.
Savara shareholders approve share increases and executive changes at annual meeting
Savara Inc. (NASDAQ:SVRA) shareholders approved significant corporate changes, including doubling the authorized common stock to 600 million shares and increasing the shares for the 2024 Omnibus Incentive Plan. The company also announced the appointment of Robert Lutz as Chief Financial and Operating Officer, effective July 15, following David Lowrance's resignation due to health reasons. These decisions were made at the annual meeting on June 4 and reflect a period of growth for the biotech firm, which has seen a 107% return over the past year.
SVRA News | SAVARA INC (NASDAQ:SVRA)
This article provides a list of recent news and announcements concerning Savara Inc. (NASDAQ: SVRA). Key updates include a Chief Financial and Administrative Officer transition, participation in the 2026 Jefferies Global Healthcare Conference, and presentations of new biomarker and long-term efficacy data from the IMPALA-2 Phase 3 clinical trial of Molgramostim. The company also announced new exercise capacity data from the same trial and reported its first-quarter financial results.
Savara CFO Dave Lowrance steps down; COO Robert Lutz takes on CFO role amid leadership reshuffle
Savara Inc. announced that CFO and Administrative Officer Dave Lowrance will resign on July 15, 2026, due to health reasons. The company will separate the financial and administrative responsibilities, with current COO Robert Lutz stepping into the CFO role. This leadership restructuring aims to ensure continuous effective financial management as Savara advances its biopharmaceutical programs.
Savara CFO Dave Lowrance to step down, Robert Lutz to expand role
Savara Inc. announced that CFO Dave Lowrance will step down on July 15, 2026, due to health reasons after nearly ten years with the company. Robert Lutz, current COO, will assume the additional role of CFO. Lowrance played a significant role in guiding the company through capital raises and its Nasdaq listing, leaving Savara with substantial liquidity and a strong stock performance.
Savara (SVRA) expands share capacity and appoints Robert Lutz as CFO/COO
Savara Inc. stockholders have approved a significant increase in the company's authorized common stock, from 300 million to 600 million shares, and expanded its 2024 Omnibus Incentive Plan by 18.9 million shares. Concurrently, Robert Lutz has been appointed as the new Chief Financial and Operating Officer, effective July 15, 2026, following David Lowrance's resignation due to health reasons. The changes provide Savara with greater flexibility for capital-raising and equity compensation, alongside a leadership transition in its finance and operations departments.
Savara Announces Chief Financial and Administrative Officer Transition
Savara Inc. announced a significant leadership transition, with Dave Lowrance stepping down as Chief Financial and Administrative Officer for health reasons, effective July 15, 2026. Robert Lutz, the current Chief Operating Officer, will assume the combined role of Chief Operating and Financial Officer. This change involves separating the financial and administrative responsibilities of the previous role, with administrative duties distributed among the senior leadership team.
SVRA - Savara Inc Stock Price and Quote
This article provides a comprehensive overview of Savara Inc. (SVRA) stock, including its latest close price, financial statistics, key ratios, and performance metrics. It also lists recent analyst ratings and a detailed timeline of company news, focusing on clinical trial data, regulatory submissions for MOLBREEVI*, and corporate announcements. Additionally, insider trading activities for the company's executives and directors are presented.
SVRA: All proposals, including director elections and plan amendments, were approved
Savara, Inc. (SVRA) held its 2026 Annual General Meeting where all proposed items, including director elections, amendments to its certificate of incorporation and incentive plan, auditor ratification, and executive compensation, were approved. The meeting concluded with a Q&A session for stockholders. This information is based on an AI-generated summary of the AGM audio transcript from June 4, 2026.
Oppenheimer Maintains Savara(SVRA.US) With Buy Rating, Maintains Target Price $11
Oppenheimer has reiterated its Buy rating for Savara (SVRA.US) and maintained its price target of $11. This indicates continued confidence in the company's prospects from the investment firm.
Savara (NasdaqGS:SVRA) Stock Forecast & Analyst Predictions
Savara (SVRA) is forecast to achieve significant growth in earnings and revenue, with analysts predicting the company to become profitable by 2028. The company's lead drug candidate, MOLBREEVI, for autoimmune pulmonary alveolar proteinosis (aPAP), has shown promising Phase 3 clinical trial results and received various regulatory designations, though its BLA submission has faced delays. Recent insider transactions indicate both buying and selling activity, and the company has experienced shareholder dilution and continued unprofitability, with revenue forecasts being revised downwards.
Savara Inc stock (US80633A1025): Jefferies conference appearance keeps rare-disease biotech in focus
Savara Inc. (SVRA), a U.S.-based rare respiratory disease biotech, announced its participation in the 2026 Jefferies Global Healthcare Conference in New York, aiming to increase visibility among institutional investors. The company's stock currently trades around $5.20 with a market capitalization of approximately $1.07 billion, reflecting its clinical-stage status. This conference engagement is crucial for Savara to communicate its strategic progress and clinical milestones to investors in the specialized rare disease sector.
Savara Announces Participation in the 2026 Jefferies Global Healthcare Conference
Savara Inc. (Nasdaq: SVRA), a biopharmaceutical company specializing in rare respiratory diseases, will participate in the 2026 Jefferies Global Healthcare Conference. Management will host one-on-one meetings and a fireside chat on June 3rd at 11:05 AM ET. The event's live webcast will be available on the company's website.
Rare lung disease biotech Savara heads to Jefferies investor conference
Savara Inc., a clinical-stage biopharmaceutical company specializing in rare respiratory diseases, announced its participation in the 2026 Jefferies Global Healthcare Conference. Members of the management team will host one-on-one meetings and a fireside chat on June 3rd. The company is currently developing MOLBREEVI for autoimmune pulmonary alveolar proteinosis.
Savara Announces Participation in the 2026 Jefferies Global Healthcare Conference
Savara Inc., a clinical stage biopharmaceutical company, announced its participation in the 2026 Jefferies Global Healthcare Conference. Members of the management team will host one-on-one meetings and a fireside chat on June 3rd at 11:05 AM ET in New York. A live webcast and replay will be available on the company's website.
New aPAP Phase 3 Data and Wider Losses Might Change The Case For Investing In Savara (SVRA)
Savara Inc. reported positive Phase 3 IMPALA-2 data for nebulized molgramostim, showing improved exercise capacity in adults with autoimmune pulmonary alveolar proteinosis (aPAP), reinforcing its clinical package. Despite a wider quarterly net loss of US$37.28 million, the company's investment narrative still hinges on molgramostim's potential approval and its upcoming FDA PDUFA date. The new data supports the drug's role in aPAP treatment but doesn't change the underlying regulatory and commercial execution risks.
Savara Presented New Biomarker Data from the IMPALA-2 Phase 3 Clinical Trial of Molgramostim Inhalation Solution (Molgramostim) in Autoimmune Pulmonary Alveolar Proteinosis (aPAP) at the American Thoracic Society (ATS) International Conference 2026
Savara Inc. presented new biomarker data from its IMPALA-2 Phase 3 clinical trial of molgramostim inhalation solution for autoimmune pulmonary alveolar proteinosis (aPAP) at the ATS 2026 International Conference. The data showed that molgramostim significantly improved pulmonary gas transfer and decreased levels of disease-related biomarkers like LDH, CYFRA 21-1, and KL-6 compared to placebo. Strong correlations were observed between these biomarker decreases and improvements in lung function, supporting molgramostim's therapeutic potential for aPAP.
